Despite the interest for the kickoff of recreational cannabis sales in Canada, the medical market has shown a consistent growth with new opportunities. A cannabis streaming company inked a deal with the potential to get ahead of the curve in the distribution of medical cannabis in Canada.
Cannabis Wheaton Income (TSXV:CBW), as president Hugo Alves told the Investing News Network (INN), was “willing to take a bet” and pursue an arrangement with a national chain of undisclosed independent pharmacies, announced on September 20.
After deciding they wanted to be a part of the way medical cannabis is distributed, Cannabis Wheaton’s research pointed them to the reach of pharmacies. As the deal stands, Cannabis Wheaton will monitor and control the retail space dedicated to medical cannabis, provided by their streaming partners. That is if this model becomes legal eventually.
Deal fringes on change in legality of distribution models for medical cannabis
When asked if he had any indication to be optimistic about an upcoming change in the law to allow this plan to come to fruition, Alves told INN he wasn’t aware of anything being done or discussed. Instead, Alves pointed to the differences between the distribution of recreational and medical cannabis.
“I know that pharmacies continue to be actively involved in trying to have their voice heard at a policy level,” Alves said. “We’re willing to take a bet that pharmacies will be included in the distribution channels for medical cannabis.”
This group, according to Alves operates 40 pharmacies in Canada and is focused on the construction of a “responsible retailing program,” that will serve consumers by providing them with education on cannabis products. Alves said this proposed model can become a viable supplement to the current delivery of medical cannabis.
Health Canada recently released a new batch of information on the number of medical cannabis users across the country. The data collected includes information for the first quarter of the fiscal 2017-2018 year, meaning April, May, and June.
Set to be negotiated on a jurisdiction by jurisdiction basis, the potential profits from this deal will be distributed through a “profit-sharing arrangement.”
“In consideration for such exclusivity, Cannabis Wheaton will issue the Pharmacy Group warrants to purchase up to 1,000,000 common shares of the Company at an exercise price of $1.00 per common share for a period of 5 years,” the company announced.
This story has been updated to reflect the complete name of Cannabis Wheaton Income.
Don’t forget to follow us @INN_LifeScience and @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Agreement propels development of safe and effective proprietary products and formulations for the emerging psychedelic industry
Optimi Health Corp. (CSE: OPTI) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce that effective January 4, 2021, it entered into a lab services agreement with Numinus Wellness Inc. (“Numinus“). Recognized as an early leader in developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), Numinus is aiding Optimi’s mission to further the research and development of Canadian-grown psilocybin-producing mushrooms and related product formulations.
Nextleaf Solutions Provides a Corporate Update and Comments on Financial Results from the First Quarter
Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (“Nextleaf”, “OILS”, or the “Company”), the world’s most innovative cannabis processor, is pleased to provide shareholders with the following corporate update:
Nextleaf Comments on Financial Results from Q1 Financials
Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”) reported its second quarter results for the period ended December 31, 2020. A complete set of financial statements and Management’s Discussion & Analysis has been filed at www.sedar.com. All dollar figures are quoted in Canadian dollars.
The second quarter of FY21, saw continued momentum for the Company despite ongoing pandemic related challenges. Net revenue grew 8% to $745,748 from $689,276 versus the same quarter year ago. The Company also saw significant improvement on its bottom line, reducing its net loss by 50% from ($.956) million to ($.481) million, year over year for the quarter, as a result of improved gross margin and cost management efforts. On December 9, 2020, the company announced the closing of the acquisition of substantially all of the assets of Lexaria Canpharm (“Canpharm“), the cannabis products division of Lexaria Biosciences, resulting in the addition of a new B2B Line of Business.
FinCanna Capital – The Only Publicly Traded, Royalty-Focused Company for the Licensed U.S. Cannabis Industry Provides Corporate Update
Royalty Model Provides Access to Early Stage Licenced U.S. Cannabis Companies and Leverage to High-Margin Revenues
FinCanna Capital Corp. (“FinCanna” or the “Company”) (CSE:CALI), a royalty company for the licensed U.S. cannabis industry, is pleased to provide a corporate update further to its recently announced upsized financing of $2 million
Significant progress made as Numinus-sponsored PRIME study on psilocybin-assisted psychotherapy for opioid, stimulant and/or alcohol use disorders enters pre-implementation stage
Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), and Syreon Corporation (Syreon), a global contract research organization with expertise in conducting clinical trials across a broad range of diseases, are pleased to share that significant progress has been made in the single-arm, open-label compassionate access 1 trial of Psilocybin-Research Intervention with Motivational Enhancement (PRIME) for substance use disorders. Currently in the development stage, the PRIME study will assess the efficacy and safety of psilocybin-assisted motivational enhancement therapy.